Systemic cardiovascular stress under androgen deprivation: emergence of a high risk cardioncological phenotype in primary care prostate cancer patients

Clicks: 1
ID: 323360
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #158 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Cardiovascular disease is one of the leading causes of morbidity and mortality in patients with prostate cancer. This is driven by the high prevalence of cardiovascular risk factors (CVRF) in this population and the potential for androgen deprivation therapy (ADT) to exacerbate cardio-metabolic risk. Aim The aim of this study was to characterise the development of new and worsening CVRF in patients with an established diagnosis of prostate cancer treated with ADT in a primary prevention setting. Methods This was a multicentric cohort study. Data were collected from four primary care centres, with data-sharing agreements, in place prior to extraction. Patients were included if they had a biopsy-confirmed diagnosis of prostate cancer and had received ADT. Baseline patient characteristics, including demographics, CVRF, cardiovascular disease history, cancer characteristics and cancer treatment prior to ADT initiation, were collected and analysed. The primary endpoint was the composite of new or worsening hypertension, diabetes, dyslipidaemia, and/or obesity during or after ADT. The secondary endpoint of Major Adverse Cardiovascular Events (MACE) included a composite of acute vascular events, revascularisation, heart failure and cardiovascular death. Results A total of 116 patients were included. The median age at ADT initiation was 74 years (IQR: 70–79). At baseline, hypertension was present in 47.4% of patients, dyslipidaemia in 12.9%, and diabetes mellitus in 19%. Seventeen patients (14.7%) had a history of coronary artery disease, 19 (16.3%) had atrial fibrillation, 3 (2.6%) had structural heart disease, and 2 had a left ventricular ejection fraction <50% prior to ADT initiation (Table 1). Cancer-related characteristics are summarised in Table 2. Following ADT commencement, 48 patients (41.4%) developed new or worsening CVRF. Patients reaching the primary endpoint had a higher baseline prevalence of dyslipidaemia (29% vs 9%), hypertension (60% vs 39%), and erectile dysfunction (36% vs 20%). MACE occurred in 10 patients. At final follow-up, 10 patients had died, of whom two deaths were due to cardiovascular causes. Conclusions In this real-world, primary care cohort, a high burden of baseline CVRF was observed in patients with prostate cancer commencing ADT. Over almost half (46.5%) developed new or worsening CVRF following ADT initiation and/or experienced MACE, with those reaching the primary endpoint demonstrating a higher CV risk profile at baseline. These findings underscore the importance of systematic cardiovascular risk assessment prior to ADT and the need for more formalised collaboration between oncology, cardiology, and primary care to reduce cardiovascular morbidity and mortality globally in the prostate cancer population.Table 1– Demographic characteristics Table 2– Cancer related characteristics
Reference Key
openalex_W7172252698 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M Andres, K Patel, M S Nazir, V Khoo, A R Lyon, S Ramalingam
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.050
URL
https://doi.org/10.1093/eurheartjsupp/suag097.050
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.